Top

Reactions Weekly

Published in:

01-01-2023 | Rituximab | Case report

Antineoplastics

Hyperprogressive primary disease, lack of efficacy and off-label use: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Zhang X, et al. Nivolumab-caused hyperprogression of diffuse large B-cell lymphoma of the testis and spontaneous remission of type 2 diabetes mellitus in an elderly patient: A case report. Anti-Cancer Drugs 32: 575-579, No. 5, Jun 2021. Available from: URL: http://doi.org/10.1097/CAD.0000000000001033

Title: Antineoplastics
Hyperprogressive primary disease, lack of efficacy and off-label use: case report
Publication date: 01-01-2023
Publisher: Springer International Publishing
Keywords: Rituximab
Ibrutinib
Rituximab
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-30281-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antineoplastics

Hyperprogressive primary disease, lack of efficacy and off-label use: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Cabozantinib/ipilimumab/nivolumab

Carbamazepine

Multiple drugs

Cyclophosphamide/dexamethasone/diuretics

Amiodarone/lidocaine/procainamide

Sertraline